Phase I study of oral ridaforolimus in combination with paclitaxel and carboplatin in patients with solid tumor cancers
Số trang: 8
Loại file: pdf
Dung lượng: 731.14 KB
Lượt xem: 4
Lượt tải: 0
Xem trước 2 trang đầu tiên của tài liệu này:
Thông tin tài liệu:
Ridaforolimus is a mammalian target of rapamycin inhibitor that has activity in solid tumors. Paclitaxel and carboplatin have broad antineoplastic activity in many cancers. This phase I trial was conducted to determine the safety profile, maximal tolerated dose, and recommended phase II dose and schedule of oral ridaforolimus combined with paclitaxel and carboplatin in patients with solid tumor cancers.
Nội dung trích xuất từ tài liệu:
Phase I study of oral ridaforolimus in combination with paclitaxel and carboplatin in patients with solid tumor cancers
Nội dung trích xuất từ tài liệu:
Phase I study of oral ridaforolimus in combination with paclitaxel and carboplatin in patients with solid tumor cancers
Tìm kiếm theo từ khóa liên quan:
BMC Cancer Oral ridaforolimus Phase 1 trial Paclitaxel and carboplatin combination Solid tumorsGợi ý tài liệu liên quan:
-
Differences between physician and patient preferences for cancer treatments: A systematic review
13 trang 169 0 0 -
6 trang 166 0 0
-
Immune checkpoint inhibitors and their impact on liver enzymes and attenuation
7 trang 139 0 0 -
2011–2021 rising prevalence of HPV infection among oropharyngeal carcinoma in France
9 trang 110 0 0 -
12 trang 88 0 0
-
19 trang 72 0 0
-
17 trang 60 0 0
-
9 trang 37 0 0
-
11 trang 35 0 0
-
12 trang 34 0 0